NEOVASC INC | CIK:0001399708 | 3

  • Filed: 5/16/2018
  • Entity registrant name: NEOVASC INC (CIK: 0001399708)
  • Generator: Merrill
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1399708/000104746918003806/0001047469-18-003806-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1399708/000104746918003806/nvcn-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001399708
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory

    (l)          Research and development

    The Company is engaged in research and development. Research costs are expensed as incurred. Development costs are expensed in the period incurred, unless they meet the criteria for capitalization. The criteria include that development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Other development expenditure is recognized in profit or loss as incurred. Management reviews the applicable criteria on a regular basis and if the criteria are no longer met, any remaining unamortized balance is written off as a charge to profit or loss. Research and development costs are reduced by any scientific research and experimental development tax credits to which the Company is entitled.